rFSH in medically assisted procreation: Evidence for ovarian follicular hyperplasia and interest of mass spectrometry to measure 17-hydroxyprogesterone and Δ4-androstenedione in serum
| Autor: | Jean Guibourdenche, M.L. Hebert-Schuster, N. Lahlou, V. Gayet, M.-C. Menet, M.-C. Leguy, L. Marcellin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.drug_class Estrone Ovary Biochemistry Mass Spectrometry 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Ovarian Follicle Internal medicine Follicular phase medicine Humans music Molecular Biology Testosterone Retrospective Studies 030219 obstetrics & reproductive medicine music.instrument Hyperplasia business.industry 17-alpha-Hydroxyprogesterone Reproduction Androstenedione Androgen medicine.disease Follicular hyperplasia Recombinant Proteins 030104 developmental biology medicine.anatomical_structure chemistry Hydroxyprogesterone Female Follicle Stimulating Hormone business |
| Zdroj: | Molecular and cellular endocrinology. 450 |
| ISSN: | 1872-8057 |
| Popis: | Ovarian monitoring requires the determination of serum estradiol and progesterone levels. We investigated whole follicular steroidogenesis under rFSH in medically assisted procreation (MAP: 26 IVF, 24 ICSI) compared to 11 controls (IUI). Estrone, estradiol, Δ4-androstenedione, testosterone, progesterone and 17-hydroxyprogesterone were measured by immunoassay and mass spectrometry except for estrogens. At the start of a spontaneous or induced cycle, steroids levels fluctuated within normal ranges: estradiol (314–585 pmol/L), estrone (165–379 pmol/L) testosterone (1.3–1.6 nmol/L), Δ4-androstenedione (4.5–5.6 nmol/L), 17-hydroxyprogesterone (2.1–2.2 nmol/L) and progesterone (1.8–1.9 nmol/L). 17-hydroxyprogesterone, Δ 4-androstenedione and estradiol predominated. Then estradiol and oestrone levels rise, but less markedly for oestrone in IUI. In MAP, rFSH injections induce a sharp increase in estrogens associated with a rise in 17-hydroxyprogesterone and Δ4-androstenedione levels, disrupting oestrogen/androgen ratios. rFSH stimulation induces an ovarian hyperplasia and Δ4pathway which could become abnormal. Determining 17-hydroxyprogesterone and Δ4-androstenedione levels with LC-MS/MS may therefore be useful in managing recurrent MAP failures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect